{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T16:01:51Z","timestamp":1772899311954,"version":"3.50.1"},"reference-count":44,"publisher":"American Society of Clinical Oncology (ASCO)","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Next-generation sequencing (NGS) is recommended for patients with metastatic prostate cancer (PC). Nationwide, testing rates are low. Whether PC disease characteristics and courses differ between those with and without NGS testing is unknown. We identified predictors of testing, explored likely reasons for lack of testing, and compared survival between those with and without testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>We retrospectively reviewed patients with metastatic PC initially seen between 2020 and 2022 at Johns Hopkins. Clinical data and reasons for nontesting were abstracted from the electronic medical record. We conducted a logistic regression assessing predictors of NGS testing, adjusting for age, Gleason grade, marital status, and metastatic diagnosis year. We used Cox regression to compare overall survival, defined from the time patients had both a metastatic diagnosis and a visit at our institution until death\/last follow-up, between those tested and not tested. We adjusted for age, Gleason grade, initial metastasis (M) stage, comorbidities, and time from metastatic diagnosis to first visit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Of the 435 patients, 257 (59%) had NGS testing. Older patients were less likely to have testing (adjusted odds ratio [aOR], 0.96 [95% CI, 0.94 to 0.98]). Unmarried patients were less likely to have testing (aOR, 0.62 [95% CI, 0.38 to 1.01]). Patients with Gleason Grade Group 5 were more likely to undergo testing than patients with Groups 1-3 (aOR, 1.86 [95% CI, 1.14 to 3.04]). Among those without testing, 139 (78%) had at least one potential reason for lack of testing in the medical record. The most common reason for nontesting was patient\/disease factors (37%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Older and unmarried men with metastatic PC were less likely to obtain NGS testing, whereas those with high Gleason grade were more likely. Interventions are needed to improve testing rates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/op-25-00688","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T20:59:06Z","timestamp":1771534746000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Characteristics and Outcomes of Patients With Metastatic Prostate Cancer With and Without Next-Generation Sequencing Testing"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8059-0124","authenticated-orcid":true,"given":"Madelyn F.","family":"Klugman","sequence":"first","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8388-6297","authenticated-orcid":true,"given":"Hua-Ling","family":"Tsai","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4592-2065","authenticated-orcid":true,"given":"Yasaman","family":"Iranmanesh","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1755-9957","authenticated-orcid":true,"given":"Ifeoma","family":"Nwigwe","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6724-9546","authenticated-orcid":true,"given":"Laura A.","family":"Sena","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8787-3271","authenticated-orcid":true,"given":"Mario A.","family":"Eisenberger","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7384-1853","authenticated-orcid":true,"given":"Otis","family":"Brawley","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2852-7280","authenticated-orcid":true,"given":"Adel","family":"Mandl","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2780-5100","authenticated-orcid":true,"given":"Mark C.","family":"Markowski","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0031-9655","authenticated-orcid":true,"given":"Emmanuel S.","family":"Antonarakis","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3658-1858","authenticated-orcid":true,"given":"Channing J.","family":"Paller","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5442-515X","authenticated-orcid":true,"given":"Samuel R.","family":"Denmeade","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7908-1215","authenticated-orcid":true,"given":"Michael A.","family":"Carducci","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1084-6918","authenticated-orcid":true,"given":"Jenna V.","family":"Canzoniero","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0582-8005","authenticated-orcid":true,"given":"Kala","family":"Visvanathan","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD"},{"name":"Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2653-4110","authenticated-orcid":true,"given":"Catherine H.","family":"Marshall","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-22-1038"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02608"},{"key":"e_1_3_5_4_2","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Prostate Cancer V1.2025 \u00a9 National Comprehensive Cancer Network Inc. 2024."},{"key":"e_1_3_5_5_2","volume-title":"Pembrolizumab Approved for Tumors with Specific Genetic Features\u2014NCI","year":"2017","unstructured":"Pembrolizumab Approved for Tumors with Specific Genetic Features\u2014NCI. 2017. https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2017\/fda-pembrolizumab-genetic-features"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0327"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390166"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00339"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.23186"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00568-1"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.01023"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.23.00253"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.0851"},{"key":"e_1_3_5_14_2","article-title":"Disparities in biomarker testing and clinical trial enrollment among patients with lung, breast, or colorectal cancers in the United States","author":"Bruno DS","unstructured":"Bruno DS, Hess LM, Li X, et al: Disparities in biomarker testing and clinical trial enrollment among patients with lung, breast, or colorectal cancers in the United States. JCO Precis Oncol 10.1200\/PO.21.00427","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.0499"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2024.07.113"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2390821"},{"key":"e_1_3_5_18_2","doi-asserted-by":"crossref","unstructured":"Exempt Research. Title 45 C.F.R. 1982;\u00a7:46.104","DOI":"10.1177\/002248718203300610"},{"key":"e_1_3_5_19_2","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Prostate Cancer V1.2020 \u00a9 National Comprehensive Cancer Network Inc. 2020."},{"key":"e_1_3_5_20_2","unstructured":"Mohler JL Higano CS Schaeffer EM et al: Current recommendations for prostate cancer genetic testing: NCCN prostate guideline. 2019"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.4338\/ACI-2013-12-RA-0100"},{"key":"e_1_3_5_22_2","volume-title":"Improve Outcomes and Enhance the Patient Experience | CRISP","author":"Home","year":"2024","unstructured":"Home: Improve Outcomes and Enhance the Patient Experience | CRISP. 2024. https:\/\/www.crisphealth.org\/"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2021.03.011"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqv023"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1802313"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2007.03.011"},{"key":"e_1_3_5_27_2","volume-title":"StataCorp. 2023. Stata statistical softare: release 18","unstructured":"StataCorp. 2023. Stata statistical softare: release 18. College Station, TX: StataCorp LLC"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4995"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603144"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2016.07.004"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.19.00561"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-16464-6"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0429"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e18743"},{"key":"e_1_3_5_35_2","article-title":"Factors affecting genomic testing in prostate cancer: Results from the decision-making, experience, and confidence in Determining Genomic Evaluation (DECIDE) Survey","author":"Bitting RL","unstructured":"Bitting RL, McNair C, Wyatt AW, et al: Factors affecting genomic testing in prostate cancer: Results from the decision-making, experience, and confidence in Determining Genomic Evaluation (DECIDE) Survey. JCO Precis Oncol 10.1200\/PO-24-00821","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2020.08.004"},{"key":"e_1_3_5_37_2","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non-Small Cell Lung Cancer V.2025 \u00a9 National Comprehensive Cancer Network Inc. 2025."},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01029-8"},{"key":"e_1_3_5_39_2","volume-title":"National Comprehensive Cancer Network. Prostate Cancer (Version 2.2026)","year":"2025","unstructured":"National Comprehensive Cancer Network. Prostate Cancer (Version 2.2026). 2025. nccn.org"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.9119"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0228"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24269"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.06.033"},{"key":"e_1_3_5_44_2","article-title":"Urban-rural and socioeconomic differences in patient knowledge and perceptions of genomic tumor testing","author":"DiBiase JF","unstructured":"DiBiase JF, Scharnetzki E, Edelman E, et al: Urban-rural and socioeconomic differences in patient knowledge and perceptions of genomic tumor testing. JCO Precis Oncol 10.1200\/PO.22.00631","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_5_45_2","article-title":"Patients\u2019 expectations of benefits from large-panel genomic tumor testing in rural community oncology practices","author":"Anderson EC","unstructured":"Anderson EC, DiPalazzo J, Edelman E, et al: Patients\u2019 expectations of benefits from large-panel genomic tumor testing in rural community oncology practices. JCO Precis Oncol 10.1200\/PO.21.00235","journal-title":"JCO Precis Oncol"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-25-00688","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T20:59:34Z","timestamp":1772830774000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-25-00688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":44,"alternative-id":["10.1200\/OP-25-00688"],"URL":"https:\/\/doi.org\/10.1200\/op-25-00688","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"2025-07-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"OP-25-00688"}}